ライフサイエンスコーパス: medication

1 received an order for a new antihypertensive medication.

2 tes with hypertension well controlled with 1 medication.

3 ng of the brain and might be altered through medication.

4 d as HbA1c of >=6.5% and/or current diabetes medication.

5 ith self-harm independently of diagnosis and medication.

6 tors in uptitration to adequate levels of HF medication.

7 aseline IOP, and number and type of glaucoma medications.

8 achieve widespread use of these life-saving medications.

9 ch is treated with beta-adrenoceptor-agonist medications.

10 ing a 2-week withdrawal of anti-hypertensive medications.

11 minatory metabolites were related to diet or medications.

12 cess) or without (complete success) glaucoma medications.

13 5% of which was attributable to use of brand medications.

14 = 0.519) on 2.0 +/- 1.6 (P = 0.457) glaucoma medications.

15 ss all predicted lower adherence to glaucoma medications.

16 ived at least one of the nine antidepressant medications.

17 ening, behavioral counseling, and preventive medications.

18 guidelines in 2019) use of cardioprotective medications.

19 ive IOP and requirement of pressure-lowering medications.

20 at admission and 55% at discharge took >=10 medications.

21 sistant symptoms or intolerance to analgesic medications.

22 tability compared with those not taking such medications.

23 glucocorticoids and other immunosuppressive medications.

24 of interest were number of daily prescribed medications (1-2, 3-4, 5-6, 7-8, 9-10, and >= 11) and pr

25 antidepressants (17.8%), and lipid-lowering medications (16.5%).

26 d and 825 received one dose or more of study medication: 186 received placebo, 93 atogepant 10 mg onc

27 illness, 13 (12%); sleeping, 10 (9%); drugs/medication, 9 (8%); and emotion, 2 (2%).

28 als who received at least one antidepressant medication, 925 (1.36%) subsequently received a diagnosi

29 ients treated with multiple antihypertensive medications, a strategy of medication reduction, compare

30 Use of 2 or more antihypertensive medications, ACEI, and diuretics were associated with a

31 tered their eye drops, and had poor glaucoma medication adherence (defined as taking <=80% of prescri

32 Medication adherence improved from 59.9% at baseline to

33 bed medication doses assessed via electronic medication adherence monitors) who completed the 7-month

34 of your medication yesterday?" The impact of medication adherence on mean deviation (MD) over time wa

35 5.6, SD = 3.0) was inversely associated with medication adherence on univariate (P < .0001) and multi

36 tion of patients who then self-reported poor medication adherence than an automated EHR pull alone bu

37 Medication adherence was assessed by telephone from resp

38 Medication adherence was modeled as a cumulative sum of

39 Change in electronically monitored medication adherence.

40 nderstand the neural basis of antidepressant medication (ADM) response with respect to both symptom a

41 The medication administration record during admission was ex

42 ar pressure (IOP) and number of antiglaucoma medications after 6 weeks with three, six, 12, and 24 mo

43 nutrient intake as means of nutritional self-medication against bacterial infection.

44 ng spirometry results, and concurrent asthma medications (all P values < .05).

45 patients were tested ON and OFF dopaminergic medication, allowing us to measure the effect of dopamin

46 as includes discontinuation of the offending medication and following treatment guidelines for the sp

47 red questionnaires for collection of data on medication and other variables.

48 s with IOP >=21 mm Hg taking maximal topical medication and scheduled for trabeculectomy were include

49 to have an adverse event attributable to TB medication and were more likely to have an adverse event

50 ssociations between certain antihypertensive medications and death.

51 r own health, particularly when the costs of medications and healthcare appointments are at odds with

52 ems, recent healthcare experiences, need for medications and medical supplies, and basic needs of par

53 ss than or equal to 24 mm Hg with or without medications and no additional surgery defined success.

54 review of PubMed articles screened for ADHD medications and potential cardiovascular toxicity as wel

55 , hospitalizations and surgeries, as well as medications and prescribed treatment.

56 lf-care included cognitive status, number of medications and type of chronic condition.

57 tency, sleep duration, sleep efficacy, sleep medication, and daytime dysfunction were significant for

58 eatments include lifestyle modification, PPI medication, and laparoscopic fundoplication.

59 possible confounding effects of mood state, medication, and other mood comorbidities, these findings

60 nine patients (26.4%) had discontinued their medication, and six (5.5%) used ICS periodically.

61 or all-cause stroke, mortality, prescription medications, and cardiovascular disease procedures.

62 e likely White race, taking antihypertensive medications, and had lower kidney function.

63 age, preoperative IOP, preoperative glaucoma medications, and previous glaucoma surgeries.

64 at admission and 95% at discharge) took >=5 medications; and 42% at admission and 55% at discharge t

65 While some FEPs remain remitted even without medication, antipsychotic discontinuation is regarded as

66 Disappointingly, however, none of these medications appear to be more efficacious than first-gen

67 The Medication Appropriateness Index and the Prescribing Fra

68 Medications approved to treat Alzheimer disease (donepez

69 ty value of adherence to prescribed glaucoma medication are vital to implement potentially effective

70 RP inhibitor-sensitive cancers in which oral medications are not tolerated.

71 Current medications are of limited efficacy and cause neurologic

72 y focusing on early disease and responses to medications, are required to establish successful biomar

73 a incidence and consumption of corresponding medications as the indicator of persisting symptoms.

74 ng either anticonvulsant and those taking no medications; as well as between the two anticonvulsants.

75 negative or HCV-negative participants not on medication assisted treatment (MAT) were eligible.

76 w insurance coverage, healthcare access, and medication-assisted treatment utilization among PWID in

77 isits, and 21 patients (7%) reported missing medication at more than two thirds of visits.

78 f visits, 31 patients (10%) reported missing medication at one third to two thirds of visits, and 21

79 n from prior maintenance medication to study medication at randomization.Methods: Exacerbations and c

80 in participants who were not taking a statin medication at the time of ERCP, while 363 participants w

81 llow-up, 112 patients (37%) reported missing medication at up to one third of visits, 31 patients (10

82 less likely to be prescribed cardiovascular medications at discharge.

83 n <3 years) who were not taking dopaminergic medications at enrollment.

84 ients with hypertension receiving at least 2 medications at maximum doses or more than 2 medications

85 medications at maximum doses or more than 2 medications at moderate doses and with a body mass index

86 ERCP, while 363 participants were on statin medications at the time of ERCP; 118 and 245 participant

87 Efficacious medication-based treatments are available and widely use

88 a minimum of two prescriptions for diabetes medications between January 2006 and January 2019 were i

89 nostic factors to initiate stepdown included medication burden, but not medication side effects.

90 The cumulative body of data showed that ADHD medications cause modest elevations in resting heart rat

91 ing us to measure the effect of dopaminergic medication changes on reward sensitivity.

92 r usual care (control, n = 287), in which no medication changes were mandated.

93 tario Health Insurance Plan, expert opinion, medication claims datasets, and Ontario Drug Benefit For

94 s, patient-reported outcomes, information, a medication coach, and eConsultations.

95 A-approved drugs clearly shows that multiple medications compete for the same binding sites, indicati

96 , antilymphocyte therapy, recipient age, and medication compliance (all P < 0.001).

97 5 patient group direction user nurse-patient medication consultations.

98 datasets, and Ontario Drug Benefit Formulary medication consumption costs.

99 pectives of patients with chronic illness on medication cost and cost discussions.

100 logistic regression to identify patient and medication cost characteristics associated with voucher

101 of these findings and consider the impact of medication cost on their patients' ability to adhere to

102 responses to 7 survey items that dealt with medication cost-related issues to any/all of a participa

103 , but the magnitude and distribution of PrEP medication costs across the health care system are unkno

104 Out-of-pocket medication costs for patients who have heart failure wit

105 related issues to any/all of a participants' medication: couldn't afford a prescribed medication; ski

106 imes, better knowledge and perceptions about medications; (d) Self-management-facilitated by educatio

107 ere general enthusiasm for decision aids for medication decisions, openness on the part of patients t

108 surgery, IOP and the number of IOP-lowering medications decreased significantly by 42.3% (P < 0.0001

109 The number of antiglaucoma medications did not change in both groups (p > 0.05) and

110 7; 95% confidence interval [CI], 1.18-1.58), medication dispensing reviews (aHR, 1.22; 95% CI, 1.10-1

111 including retention in HIV care monitoring, medication dispensing reviews, and the presence of a pee

112 , it is paramount that the administered pain medication does not disrupt the physiological mechanisms

113 rence (defined as taking <=80% of prescribed medication doses assessed via electronic medication adhe

114 dn't afford a prescribed medication; skipped medication doses to save money; took less medicine to sa

115 pplications as well as simplification of the medication dosing regimen.

116 nts (3.5%) required discontinuation of these medications due to corrected QT interval prolongation.

117 re frequently coprescribed with psychotropic medication during pregnancy and are associated with ante

118 p, and the same eye treated with a different medication during the observation period was considered

119 Immunosuppressive maintenance medications during the first 3 years postoperatively wer

120 ship between safety emphasis and the fear of medication error reporting among Chinese nurses.

121 rarchy of Authority, and the Nurses' Fear of Medication Error Reporting.

122 effect of safety emphasis on nurses' fear of medication error reporting.

123 t changes with age, and the effects of diet, medications, ethnicity, geography, and lifestyle.

124 electronic reminder and support systems (eg, Medication Event Monitoring System, smartphone), and dif

125 Total ophthalmic medication expenditure in the United States increased si

126 ary TB, pregnancy, a previous second-line TB medication exposure, or drug resistance to pyrazinamide,

127 D and failed to respond to an antidepressant medication for MDD.

128 Most participants delayed using medication for symptoms due to misperceptions about inha

129 It is used in medication for treating various diseases like cancer, ul

130 tient-Activation Tool for Intensification of Medications for Chronic Heart Failure with Reduced Eject

131 verall and comparative efficacy of different medications for induction and maintenance of remission i

132 e-in-differences methods to assess trends in medications for OUD by referral source.

133 ferred by criminal justice agencies received medications for OUD, which was significantly less than t

134 orld Health Organization's List of Essential Medications for treating non-resistant malaria, rheumato

135 Widespread use of these medications forced overwhelmed health care systems to se

136 Eighteen medication-free individuals with MDD currently in a majo

137 <20% from baseline, or increase in glaucoma medications from baseline.

138 , who had a documented failure of preventive medications from two to four drug categories in the past

139 Data included ART use and anti-tuberculosis medications grouped according to WHO effectiveness categ

140 ere less likely to be treated with LT versus medication (>=81 years of age vs. 66-70 years of age: OR

141 und that HD patients taking antidopaminergic medication had a slower progression in chorea and irrita

142 All medications have adverse effects.

143 Two candidate medications have been widely discussed: remdesivir and h

144 Some second-generation antiseizure medications have shown advantages in tolerability and sa

145 fficacious than first-generation antiseizure medications, highlighting the need for novel strategies

146 uding comorbid conditions, health behaviors, medication history, site of care, and urban versus rural

147 ary outcomes were number of antihypertensive medications, hypertension remission, and BP control acco

148 to identify patients' noncompliance to their medications identified a larger proportion of patients w

149 n the development of anaphylaxis to food and medication in patients at risk of tick bites including t

150 Payments for PrEP medication in the IQVIA database in 2018 totaled $2.08 b

151 ssfully managed with additional IOP-lowering medications in a majority of cases and did not have a si

152 T was 21.9+/-5.2 mmHg while taking 2.0+/-1.2 medications in eyes with successful SLT, compared with 1

153 lows patients to self-administer intravenous medications in small bolus doses.

154 ittle is known about coprescriptions of both medications in this setting.

155 rapamycin is typically an immunosuppressive medication, in the context of sepsis, rapamycin has the

156 f anesthesia, preparation, or post-injection medication, increased the risk of a complication.

157 Medication intake frequency (%) was compared using uncon

158 here was a significantly higher frequency of medication intake related to cardiovascular disease and

159 In 2011, inclusion of injectable medications into an expanded ESKD payment bundle prompte

160 The utility of PZQ as an essential medication is, however, intertwined with a stark gap in

161 Deprescribing of antihypertensive medications is recommended for some older patients with

162 drawn to assess the impact of stepping down medication: mean age 50.4 years, 39.4% males, 39,881 ste

163 -onset administration of the type 2 diabetes medication metformin reduces mitochondrial respiration t

164 tabolite levels in clinical samples in which medication might confound findings.

165 ma reported they could not afford prescribed medication more frequently than participants without gla

166 atients who had received prior antimicrobial medications (n = 603) had significantly higher PCR/ESI-M

167 ower coefficient of variation ratio (CVR) in medication-naive patients (logCVR = -0.49 [95% CI, -0.78

168 Every antiseizure medication needs to be assessed individually, but overal

169 Cancer patients receive numerous medications not only to combat cancer but also to allevi

170 39, 56%), 879 involved the provision of 1357 medications (nurse prescribers=399, 54%; patient group d

171 er, one-third were prescribed a higher-level medication, of whom half had no reliever prescription or

172 Two medications often used for treatment of immune-mediated

173 There were no significant benefits of medication on likelihood of smoking cessation in 2 trial

174 es in total UPDRS score in the antiparkinson medication ON state over 36 months for isradipine and pl

175 full efficacy of conventional antipsychotic medication on SZ symptomatology.

176 I to III score measured in the antiparkinson medication "ON" state between baseline and 36 months.

177 betes is managed through diet, exercise, and medications only.

178 determine whether neuropsychiatric history, medication or family history of neuropsychiatric disorde

179 s IOP >21 mmHg on maximum tolerated glaucoma medications or progressive visual field and optic nerve

180 likely to have an adenoma than those taking medication (OR = 2.38, 95% CI:1.09-5.2, p = 0.03).

181 The reduction was mainly seen for stimulant medication (OR, 0.72; 95% CI, 0.66-0.77); nonstimulant m

182 jects (46%) reported never missing a dose of medication over all available follow-up, 112 patients (3

183 Being OFF dopaminergic medication overnight did not modulate pupillary reward s

184 st in a model of opioid induced hyperalgesia/medication overuse headache in Dlx-DOR conditional knock

185 nted higher Glx compared to those with mixed medications (p = 0.026).

186 5.0 mmHg (P < 0.0001) while taking 2.1+/-1.3 medications (P = 0.52) in eyes with SLT failure.

187 57), mean IOP (P = .707), number of glaucoma medications (P = 1.000), bleb height (P = .625), bleb ex

188 roup of HD patients who were prescribed such medications part way through the study (n=90) and compar

189 of the world's population takes at least one medication per day.

190 Medication possession ratio (MPR) and implementation out

191 his study was to analyse adherence using the medication possession ration (MPR) and its relation to v

192 intraocular pressure (IOP) <=36 mmHg on <=4 medications preoperatively.

193 tive pain medication use, and discharge pain medication prescriptions were analyzed.

194 he Prescribing Framework were used to assess medication provision.

195 hypotony without (complete) or with glaucoma medications (qualified); and (2) at least a 20% reductio

196 eta-blocker and renin-angiotensin antagonist medication rates increased from 60.7% to 72.8%.

197 atients with coronary artery disease, statin medication rates increased from 66% to 80.1%.

198 ical conditions, outpatient antihypertensive medications, recorded symptoms, vital signs, radiographi

199 1:1 ratio) to a strategy of antihypertensive medication reduction (removal of 1 drug [intervention],

200 tion or sustained IOP control and meaningful medication reduction for up to 12 months postoperatively

201 Medication reduction was sustained in 187 (66.3%) partic

202 efined success as >=20% IOP reduction or >=1 medication reduction without an IOP lowering procedure.

203 antihypertensive medications, a strategy of medication reduction, compared with usual care, was noni

204 re physician considered them appropriate for medication reduction, were aged 80 years and older, had

205 p and rapid eye movement (REM) sleep, in six medication-refractory focal epilepsy patients during epi

206 ciated significantly with a known outpatient medication regimen (P = 0.006) and correct admission rec

207 alyzed the immunogenic effect of 4 different medication regimens: (1) conventional immunomodulators (

208 oidosis in 2%, seronegative NMOSD in 1%, and medication-related in 1%.

209 Medication-related osteonecrosis of the jaw (MRONJ) is a

210 care may be required for older patients with medication-related risk factors and ocular and systemic

211 the birth of modern psychopharmacology, that medication remains a mainstay for the acute treatment an

212 The SEE program included (1) automated medication reminders, (2) 3 in-person counseling session

213 wever, limitations associated with anti-VEGF medications require to unravel new pathways of vessel gr

214 y (ECT) is an effective treatment for severe medication-resistant depression.

215 be epilepsy (TLE) is the most common form of medication-resistant focal epilepsy in adults.

216 enteral suspension can help individuals with medication-resistant tremor, worsening symptoms when the

217 /90 mm Hg and less than 130/80 mm Hg without medications, respectively.

218 wherein it reflected general antidepressant medication responsivity and related differentially to a

219 Although use of these medications resulted in QT prolongation, clinicians seld

220 focus on treating precipitating conditions, medication review, managing distress, mitigating complic

221 ritus (RR 2.96; 95% CI 2.37 to 3.70), rescue medication (RR 3.46; 95% CI 2.79 to 4.30), sleep disturb

222 Alone, the medication score performs similarly to the Charlson como

223 EAACI criteria, and total nasal symptom and medication scores as reported with the aid of the patien

224 work with other VAS measurements and symptom-medication scores obtained concurrently.

225 Two symptom-medication scores were used: the modified EAACI CSMS sco

226 edict differential outcome to antidepressant medication (sertraline) compared with placebo.

227 stepdown included medication burden, but not medication side effects.

228 ss pollen allergy symptoms and use of rescue medication, significant in the first season after treatm

229 istries on hospitalizations and prescription medication since 1994.

230 r starting the treatment and had stopped the medication since the past 2 months.

231 ts' medication: couldn't afford a prescribed medication; skipped medication doses to save money; took

232 ta were grouped according to the eye and the medication so that an eye treated with a particular medi

233 re aged >=40 years, were taking >=1 glaucoma medication, spoke English, self-administered their eye d

234 rning variance ratios, we found an effect of medication status (Q = 16.95, p < .001) due to lower coe

235 rochemistry in BD youth that is sensitive to medication status and ADHD comorbidity.

236 are Biobank, N = 116,389) with diagnoses and medication status based on available electronic health r

237 However, we found differential effects of medication status on the association between local gluta

238 l acuity, intraocular pressure, and glaucoma medications/surgeries.

239 may ignore clinically important patterns of medication-taking behavior.

240 or observational studies have suggested that medications targeting the renin-angiotensin system, such

241 Prescription medication that blocks Kv11.1 channels lengthens the ven

242 ed response to sertraline, an antidepressant medication that targets these neurotransmitters.

243 s do not support discontinuation of ACEI/ARB medications that are clinically indicated in the context

244 A number of medications that are used in the care of patients with S

245 ty might represent a vulnerability factor to medications that interfere with sterol biosynthesis.

246 ngements, hypoxemia, or exposure to sedating medications that may have contributed to the development

247 Providers prescribing medication to patients with glaucoma should be aware of

248 n to save money; asked doctor for lower cost medication to save money; bought prescription drugs from

249 ven direct transition from prior maintenance medication to study medication at randomization.Methods:

250 There is no single intervention or medication to treat delirium, making it challenging to m

251 Medication to treat nesidioblastosis and diffuse congeni

252 Participants of Combining Medications to Enhance Depression Outcomes (CO-MED, n =

253 ed lifelong treatment with immunosuppressive medications to maintain their transplant status.

254 Tailoring postoperative medications to the type of periodontal/oral surgery perf

255 Despite the effectiveness of current medications to treat opioid use disorder, there is still

256 Those randomized to CXL regardless of medication (topical natamycin or amphotericin) had 1.32-

257 mited neurologic examination due to sedative medications until hospital day 10.

258 e was associated with older age, barriers to medication usage, poor symptom perception and failure to

259 ment participants (59.1%) reported cessation medication use (difference, 17.9% [95% CI, 6.3%-29.5%];

260 , severe IBS-D was associated with increased medication use and a negative perspective of IBS-D.

261 Statistical adjustment for antiparkinson medication use did not change the findings.

262 a home monitoring program improves HRQOL and medication use for patients with IPF.Methods: We perform

263 The cumulative incidence of medication use increased between 2000 to 2004 and 2013 t

264 ects of COVID-19, lapses in medical care and medication use must be minimized, and public health reso

265 graphics, operative data, perioperative pain medication use, and discharge pain medication prescripti

266 clinical characteristics, comorbidities, or medication use, and show the first mechanistic evidence

267 were survival rate for IOP control, glaucoma medication use, complication rate, and vision.

268 lifetime psychiatric diagnoses, psychotropic medication use, FKBP5 rs1360780 genotype, FKBP5 gene exp

269 e, management of asthma symptoms, controller medication use, increased use of a written management pl

270 anges in outcome measures, including IOP and medication use, were assessed.

271 Low dose ketamine is a leading medication used to provide analgesia in pre-hospital and

272 otential targets for repurposing of licensed medications: using Mendelian randomization, we found evi

273 ion so that an eye treated with a particular medication was considered as one group, and the same eye

274 Systemic immunosuppressive medication was more common among patients with uveitis (

275 (OR, 0.72; 95% CI, 0.66-0.77); nonstimulant medication was not associated with statistically signifi

276 umber of prior visits where a missed dose of medication was reported.

277 05), 2 (n = 355), 3 (n = 214), or 4 (n = 26) medications was 0.2 (2.8), 5.7 (3.3), 6.9 (3.7), 8.8 (5.

278 ears (P = 0.008), and the number of glaucoma medications was 2.1+/-1.4 in the tube group and 1.2+/-1.

279 Median number of preoperative glaucoma medications was 2.5 (range 0-5, mean 2.6); median number

280 rementally higher number of daily prescribed medications was found to be associated with increasingly

281 Use of a greater number of antihypertensive medications was significantly associated with thinner av

282 The mean number of antiglaucoma medications was significantly reduced from 2.66 +/- 1.1

283 esistant tremor, worsening symptoms when the medication wears off, and dyskinesias.

284 Among other factors, age and urate-lowering medication were associated with alpha- and beta-diversit

285 nd were on stable doses of anti-parkinsonian medication were eligible.

286 lated to diet/lifestyle, bowel function, and medication were studied in relation to bacterial alpha-/

287 The mean costs of medications were $228 and $324 for those undergoing 1 an

288 The top three most common medications were angiotensin-converting enzyme (ACE) inh

289 d were receiving at least 2 antihypertensive medications were included.

290 atients with T2DM, those not taking diabetes medications were more likely to have an adenoma than tho

291 ng a patient's EEG record(s) as input, which medications were noted on the matching physician report.

292 Fewer antidiarrheal medications were required in the study group, but this d

293 eduction in total number of antihypertensive medications while maintaining BP less than 140/90 mm Hg.

294 ing patient population is resistant to these medications, while off-target side effects lead to disma

295 atients aged >=40 years, taking >=1 glaucoma medication, who self-reported poor adherence) completed

296 iers to uptake of, and adherence to, current medications will need to be considered as we deepen our

297 Association of glucose-lowering medications with cardiovascular outcomes: an umbrella re

298 Multiple disease-modifying medications with regulatory approval to treat multiple s

299 There were no deaths related to the medications with the simplified monitoring approach and

300 on, "Did you happen to miss any dose of your medication yesterday?" The impact of medication adherenc